Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 5Active not recruiting 4Withdrawn 3Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Recurrence 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Completed × tisagenlecleucel × Clear all
NCT03568461 2025-10-07

ELARA

Novartis

Phase 2 Completed
98 enrolled 9 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Recurrence

NCT03610724 2024-06-20

BIANCA

Novartis

Phase 2 Completed
34 enrolled 19 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02445248 2024-04-18

JULIET

Novartis

Phase 2 Completed
115 enrolled 22 charts 1 FDA
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02435849 2024-02-13

ELIANA

Novartis

Phase 2 Completed
80 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02228096 2020-11-23

ENSIGN

Novartis

Phase 2 Completed
75 enrolled 41 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡